NASD · Healthcare · Biotechnology · USA
Oruka Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing novel monoclonal antibody treatments for psoriasis and other inflammatory and immunology conditions. The company's lead programs, ORKA-001 and ORKA-002, target specific immune pathways and incorporate half-life extension technology to reduce dosing frequency. Oruka collaborates with Paragon Therapeutics to advance its antibody development through validated mechanisms of action.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Oruka Therapeutics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on ORKA yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.